Jin Li is a Neurology physician affiliated with Texas A&M Health Science Center. OpenAlex indexes 39 publications with 449 citations (h-index 12); ClinicalTrials.gov lists 102 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
19 Bradhurst Ave
Ste. 2850
Hawthorne, NY 105322140
Telephone
914-345-1313Provider last certified this registry record 29 Nov 2021.
Clinical trials
- TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy
Sponsor: Tasly Pharmaceutical Group Co., Ltd
- A Study to Evaluate Safety, PK and Efficacy of GH55 in Combination With GH21 in Patients With Solid Tumors
Sponsor: Suzhou Genhouse Bio Co., Ltd.
- Clinical Study of CVL006 Injection in Advanced Solid Tumors
Sponsor: Convalife (Shanghai) Co., Ltd.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
23 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Alexion Pharmaceuticals, Inc.Program year202512 payments
- Globus Medical, Inc.Program year20251 payment
- UCB, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Musculoskeletal
96.5%Neuromuscular Blocker96.1%Onabotulinumtoxina100%Part B, office-administered≥39 patientsSurvival of Motor Neuron 2 Splicing Modifier0.3%Evrysdi100%Part D<11 patients+ 2 more classes in this area
Nervous system
3.1%Calcitonin Gene-related Peptide Receptor Antagonist0.5%Nurtec Odt51%Ubrelvy39%Qulipta11%Part D<11 patientsTricyclic Antidepressant0.5%Amitriptyline Hcl70%Nortriptyline Hcl30%Part D<11 patients+ 12 more classes in this area
Metabolism & gastrointestinal
0.2%Corticosteroid0.2%Prednisone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A multimodal vision-language model for comprehensive dental diagnosis and enhanced clinical practice
Nature Communications
2026 - Androgens drive SLC1A5-dependent metabolic reprogramming in polycystic ovary syndrome
Nature Communications
2025 - Biodentine Counteracts the Aging Process of Human Dental Pulp Stem Cells Through Wnt/β-Catenin Pathway
International Dental Journal
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Deep Parikh, MD
Texas A&M Health Science Center
Rosser Powitzky, MD
Texas A&M Health Science Center
Nathan Drever, MD
Texas A&M Health Science Center
Jose Pliego, MD
Texas A&M Health Science Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”